A number of cancers have been known to be the product of loss or mutation in BRG1, which includes lung cancer, small cell carcinoma of the ovary-hypercalcemic type, medulloblastoma, Burkitt’s lymphoma, and others, as the mutation of each subunit promotes oncogenesis [16,20]. This evidence concerns the gene SMARCA4 and lung cancer.